MedWatch

Analyst calls Orphazyme's 300 percent value jump "strange and noteworthy"

Danish biotech company Orphazyme experienced a dramatic value increase on the US stock exchange on Thursday, with trading of the share suspended 20 times. Nordnet analyst Per Hansen calls the increase illogical.

Photo: BRENDAN MCDERMID/REUTERS / X90143

On Thursday, Danish biotech company Orphazyme experienced a dramatic value jump on the US stock exchange.

The company ended the day with a 301 percent value increase and share price of USD 21, after trading of the share was suspended 20 times and its value peaked at USD 77.77, representing an almost 1,400 percent increase.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs